According to a new study published in Cancer Research, Australian researchers have identified a gene that plays a significant role in the development of high-grade serous ovarian cancer tumors becoming resistant to liposomal doxorubicin (commonly known as Doxil), which is commonly used to treat recurrent ovarian cancer.
Investigating the changes in a tumor from the time a woman is initially treated for ovarian cancer to when she becomes resistant to chemotherapy, researchers found significant changes. The most significant changes were found in tumors that became resistant to chemotherapy after initially responding well to it. The reduction of a specific protein, LRP1B, was associated with resistance to liposomal doxorubicin.
Click here for the abstract.